Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Journal of Pediatric Gastroenterology and Nutrition · 2026-11-05
DOI: 10.1002/jpn3.70645 ↗Abstract
Abstract Objective We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age
EUVIMED